Euroespes SA
MAD:EEP

Watchlist Manager
Euroespes SA Logo
Euroespes SA
MAD:EEP
Watchlist
Price: 0.34 EUR Market Closed
Market Cap: 4m EUR

Euroespes SA
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Euroespes SA
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Euroespes SA
MAD:EEP
Operating Income
-€1.4m
CAGR 3-Years
-59%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
Pangaea Oncology SA
MAD:PANG
Operating Income
-€2.2m
CAGR 3-Years
-18%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
No Stocks Found

Euroespes SA
Glance View

EuroEspes SA engages in the provision of biomedical services. The company is headquartered in Bergondo, La Coruna. The company went IPO on 2012-06-21. The firm operates a medical center, which focuses on the prevention, diagnosis and treatment of central nervous system disorders, such as Alzheimer and Parkinson, and other common diseases. The Company’s medical offer includes personalized treatment plans, genomic medicine, epigenetics, neuropsychology, neuro-ophthalmology, digital diagnosis, diagnostic imaging, clinical analysis and nursing services, among others. In addition, it provides pharmacogenetics services and Human Identification Genetics card, which identifies user's deoxyribonucleic acid (DNA) profile. The firm operates through a number of subsidiaries, such as in Euroespes Biotecnologia SA, Distribuidora de Productos SL and Ebiotec Pharma SL.

EEP Intrinsic Value
Not Available

See Also

What is Euroespes SA's Operating Income?
Operating Income
-1.4m EUR

Based on the financial report for Dec 31, 2023, Euroespes SA's Operating Income amounts to -1.4m EUR.

What is Euroespes SA's Operating Income growth rate?
Operating Income CAGR 5Y
-30%

Over the last year, the Operating Income growth was -23%. The average annual Operating Income growth rates for Euroespes SA have been -59% over the past three years , -30% over the past five years .

Back to Top